ストックスクリーナーアプリを入手
7.305
0.48%
0.035
前日終値:
$7.27
開ける：
$7.25
24時間の取引高:
677.80K
Relative Volume:
0.38
時価総額：
$856.82M
収益：
-
当期純損益:
$-29.07M
株価収益率:
-25.19
EPS:
-0.29
ネットキャッシュフロー:
$-31.85M
1週間 パフォーマンス:
-1.35%
1か月 パフォーマンス:
+22.77%
6か月 パフォーマンス:
+72.29%
1年 パフォーマンス:
+182.05%
1日の値動き範囲:
$7.12
$7.305
1週間の範囲:
$7.08
$7.57
52週間の値動き範囲:
$2.36
$8.11
Trevi Therapeutics Inc Stock (TRVI) Company Profile
名前
Trevi Therapeutics Inc
セクター
電話
203-304-2499
住所
195 CHURCH STREET, NEW HAVEN, CT
TRVI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
7.305 | 902.20M | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
377.71 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.66 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.63 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
668.20 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
296.01 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-05-28 | 開始されました | H.C. Wainwright | Buy |
| 2025-03-10 | 繰り返されました | Needham | Buy |
| 2025-03-10 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2024-08-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-08-30 | 開始されました | Raymond James | Outperform |
| 2024-06-13 | 開始されました | Rodman & Renshaw | Buy |
| 2023-04-12 | 開始されました | B. Riley Securities | Buy |
| 2022-11-22 | 開始されました | SVB Leerink | Outperform |
| 2019-06-03 | 開始されました | BMO Capital Markets | Outperform |
| 2019-06-03 | 開始されました | Needham | Buy |
| 2019-06-03 | 開始されました | SVB Leerink | Outperform |
| 2019-06-03 | 開始されました | Stifel | Buy |
すべてを表示
Trevi Therapeutics Inc (TRVI) 最新ニュース
Trevi Therapeutics TRVI Q2 2025 Earnings Preview Upside Potential with Positive Share Dynamics - AInvest
Is Trevi Therapeutics Inc. stock overvalued or undervaluedMassive profits - Jammu Links News
Should I hold or sell Trevi Therapeutics Inc. stock in 2025Free Investment Timing Strategies - Jammu Links News
What is the risk reward ratio of investing in Trevi Therapeutics Inc. stockUnlock daily stock market insights for success - Jammu Links News
What makes Trevi Therapeutics Inc. stock price move sharplyFree Market Dynamics Reports - Jammu Links News
Published on: 2025-08-03 17:59:19 - Jammu Links News
When is Trevi Therapeutics Inc. stock expected to show significant growthFree Buy/Sell Signal Notifications - Jammu Links News
How strong is Trevi Therapeutics Inc. company’s balance sheetUnlock powerful trading alerts for success - Jammu Links News
What analysts say about Trevi Therapeutics Inc. stockUnlock rapid growth potential in your portfolio - Jammu Links News
Why is Trevi Therapeutics Inc. stock attracting strong analyst attentionExceptional market performance - Jammu Links News
Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025 - Eastern Progress
What institutional investors are buying Trevi Therapeutics Inc. stockMarket Forecast Recommendation With Low Risk - Jammu Links News
Trevi Therapeutics Q2 Earnings: Key Updates on Chronic Cough Drug Trials Coming August 7 - Stock Titan
Is it the right time to buy Trevi Therapeutics Inc. stockEntry Signal Growth Plan For Every Investor - Jammu Links News
Trend analysis for Trevi Therapeutics Inc. this weekLow Risk Buy Zone Opportunity Watch Ongoing - metal.it
Why Trevi Therapeutics Inc. stock attracts strong analyst attentionScalable Strategy with Chart Confirmation - Newser
Has Trevi Therapeutics Inc. formed a bullish divergenceFundamental + Technical Combined Watchlist - Newser
Predicting Trevi Therapeutics Inc. trend using moving averagesRisk Balanced Picks for Safer Trading - Newser
Bullish Candlestick Pattern Forms in Trevi Therapeutics Inc.Weekly Stock Opportunity Radar Scanner Activated - metal.it
Developing predictive dashboards with Trevi Therapeutics Inc. dataDaily Market Entry Strategy with Tools - Newser
Trevi Therapeutics Inc. Earnings Report Breakdown: What Investors Should KnowWeekly Hot Stocks Based on Volume Flow - Newser
Trevi Therapeutics Inc.’s Beta Climbs After Market VolatilityAI Screening for Swing Trade Picks Finds Momentum - metal.it
Why did Trevi Therapeutics' operating expenses surge in Q3 2024? - AInvest
Trevi Therapeutics to Participate in Upcoming August Conferences - PR Newswire
Trevi Therapeutics To Participate In Upcoming August Conferences - Barchart.com
Trevi Therapeutics Inc. Shows Early Signs of Technical StrengthFast Exit and Entry Strategy Guide Offered - metal.it
Trevi Therapeutics Inc. Stock Support and Resistance Levels You Should Know Stable Profit Zone and Loss Control Analysis - beatles.ru
Is Trevi Therapeutics Inc. a growth stock or a value stockBuild a diversified portfolio for steady growth - Jammu Links News
Brokerages Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Target Price at $20.88 - Defense World
Trevi Therapeutics Inc. Stock Analysis and ForecastUnbelievable profit margins - PrintWeekIndia
Should I buy Trevi Therapeutics Inc. stock before earningsFree Capital Allocation Plans - jammulinksnews.com
What drives Trevi Therapeutics Inc. stock priceUnprecedented profit potential - PrintWeekIndia
Is Trevi Therapeutics Inc. a good long term investmentHigh-profit trading signals - Autocar Professional
Will Trevi Therapeutics Inc. stock split in the near futureMarket-leading growth rates - Jammu Links News
How Trevi Therapeutics Inc. stock reacts to Fed policy changesFree Risk Assessment Services - jammulinksnews.com
The Business Case For Buying Trevi Therapeutics Inc (NASDAQ: TRVI) Stock Now - Stocksregister
Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference - Seeking Alpha
Trevi Therapeutics Inc (TRVI) 財務データ
収益
当期純利益
現金流量
EPS
Trevi Therapeutics Inc (TRVI) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| SCIASCIA THOMAS | Chief Scientific Officer |
Mar 25 '25 |
Sale |
6.60 |
2,631 |
17,365 |
221,373 |
| GOOD JENNIFER L | President & CEO |
Mar 21 '25 |
Option Exercise |
1.43 |
5,263 |
7,526 |
218,576 |
| GOOD JENNIFER L | President & CEO |
Mar 21 '25 |
Sale |
6.58 |
5,263 |
34,625 |
213,313 |
0.14%
0.27%
大文字化:
|
ボリューム (24 時間):